高流量鼻导管治疗与无创通气在COPD轻中度高碳酸血症急性呼吸衰竭中的非劣效性随机临床试验方案
本研究为前瞻性、非盲、多中心、随机对照试验,旨在评估高流量鼻导管治疗(HFNT)相比无创通气(NIV)在改善COPD合并轻中度高碳酸血症急性呼吸衰竭患者动脉血二氧化碳分压(PaCO2)方面的非劣效性。计划纳入80例动脉pH 7.25-7.35且PaCO2≥55 mmHg的成人患者,主要结局为PaCO2下降。
要点
- HFNT可能作为NIV的替代方案用于COPD轻中度呼吸性酸中毒患者。
- 纳入标准为动脉pH 7.25-7.35且PaCO2≥55 mmHg的急性高碳酸血症呼吸衰竭成人患者。
- 主要结局为PaCO2下降,非劣效界值为10 mmHg。
核心结论
- 若HFNT不劣于NIV,则可考虑作为NIV的替代方案治疗COPD轻中度呼吸性酸中毒患者。
研究设计与样本
- 前瞻性、非盲、多中心、随机对照非劣效性试验,计划纳入80例成人患者,按1:1随机分配至NIV组或HFNT组。
主要发现
- 原文未报告研究结果。
关键数值与推荐
- 纳入标准:动脉pH 7.25-7.35且PaCO2≥55 mmHg。
- NIV设置:压力支持模式,呼气末正压3-5 cmH2O,潮气量6-8 ml/kg理想体重。
- HFNT初始设置:温度37°C,流量60 L/min。
- 样本量计算基于PaCO2标准差15 mmHg、非劣效界值10 mmHg、α误差5%、β误差80%,计算得56例,考虑脱落和非参数分析后最终为80例(每组40例)。
临床怎么用
- HFNT可能比NIV更舒适,可用于COPD急性加重恢复期患者。
- 需在2小时和6小时评估动脉血气、生命体征、呼吸频率、治疗不耐受和失败、插管需求等。
局限性
- 研究为非盲设计。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Noninvasive ventilation (NIV) is indicated to treat respiratory acidosis due to exacerbation of chronic obstructive pulmonary disease (COPD). Recent nonrandomized studies also demonstrated some physiological effects of high-flow nasal therapy (HFNT) in COPD patients. We designed a prospective, unblinded, multicenter, randomized controlled trial to assess the noninferiority of HFNT compared to NIV with respect to the reduction of arterial partial pressure of carbon dioxide (PaCO2) in patients with hypercapnic acute respiratory failure with mild-to-moderate respiratory acidosis. METHODS: We will enroll adult patients with acute hypercapnic respiratory failure, as defined by arterial pH between 7.25 and 7.35 and PaCO2 ≥ 55 mmHg. Patients will be randomly assigned 1:1 to receive NIV or HFNT. NIV will be applied through a mask with a dedicated ventilator in pressure support mode. Positive end-expiratory pressure will be set at 3-5 cmH2O with inspiratory support to obtain a tidal volume between 6 and 8 ml/kg of ideal body weight. HFNT will be initially set at a temperature of 37 °C and a flow of 60 L/min. At 2 and 6 h we will assess arterial blood gases, vital parameters, respiratory rate, treatment intolerance and failure, need for endotracheal intubation, time spent under mechanical ventilation (both invasive and NIV), intensive care unit and hospital length of stay, and hospital mortality. Based on an α error of 5% and a β error of 80%, with a standard deviation for PaCO2 equal to 15 mmHg and a noninferiority limit of 10 mmHg, we computed a sample size of 56 patients. Considering potential drop-outs and nonparametric analysis, the final computed sample size was 80 patients (40 per group). DISCUSSION: HFNT is more comfortable than NIV in COPD patients recovering from an episode of exacerbation. If HFNT would not be inferior to NIV, HFNT could be considered as an alternative to NIV to treat COPD patients with mild-to-moderate respiratory acidosis. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03370666 . Registered on December 12, 2017.
引用
- Cortegiani A, Longhini F, Carlucci A, et al. High-flow nasal therapy versus noninvasive ventilation in COPD patients with mild-to-moderate hypercapnic acute respiratory failure: study protocol for a noninferiority randomized clinical trial. Trials. 2019. PMID: 31331372. doi:10.1186/s13063-019-3514-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。